Based on these results we have initiated a randomized clinical trial to evaluate the effect of Transtuzumab administration on the disease-free survival of patients with early breast cancer and CK-19 and HER-2 mRNA-positive CTCs. This evidence concerns the gene KRT19 and breast cancer.